[{"address1": "4505 Emperor Boulevard", "address2": "Suite 200", "city": "Durham", "state": "NC", "zip": "27703", "country": "United States", "phone": "919 859 1302", "fax": "919 859 1314", "website": "https://www.biocryst.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.", "fullTimeEmployees": 536, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jon P. Stonehouse", "age": 62, "title": "CEO, President & Executive Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 1233329, "exercisedValue": 647137, "unexercisedValue": 3108646}, {"maxAge": 1, "name": "Mr. Anthony J. Doyle", "age": 43, "title": "Senior VP, CFO & Interim Principal Accounting Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 845926, "exercisedValue": 0, "unexercisedValue": 971360}, {"maxAge": 1, "name": "Ms. Alane P. Barnes", "age": 57, "title": "Senior VP, Chief Legal Officer & Corporate Secretary", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 794749, "exercisedValue": 0, "unexercisedValue": 907856}, {"maxAge": 1, "name": "Dr. Helen M. Thackray FAAP, M.D.", "age": 55, "title": "Chief Research & Development Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 976153, "exercisedValue": 0, "unexercisedValue": 148400}, {"maxAge": 1, "name": "Mr. Charles K. Gayer", "age": 52, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 794121, "exercisedValue": 0, "unexercisedValue": 381858}, {"maxAge": 1, "name": "Mr. John D. Bluth", "age": 50, "title": "Chief Communications Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stephanie  Angelini", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William P. Sheridan MBBS", "age": 68, "title": "Chief Development Officer & Interim Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 784089, "exercisedValue": 4401140, "unexercisedValue": 2673017}, {"maxAge": 1, "name": "Dr. Yarlagadda S. Babu Ph.D.", "age": 70, "title": "Chief Discovery Officer", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 691450, "exercisedValue": 1245703, "unexercisedValue": 6136468}, {"maxAge": 1, "name": "Ms. Jinky Ang Rosselli", "title": "Chief Data & Insights Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 2, "compensationRisk": 5, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://investor.shareholder.com/biocryst/index.cfm", "maxAge": 86400, "priceHint": 2, "previousClose": 8.28, "open": 8.31, "dayLow": 8.0, "dayHigh": 8.31, "regularMarketPreviousClose": 8.28, "regularMarketOpen": 8.31, "regularMarketDayLow": 8.0, "regularMarketDayHigh": 8.31, "beta": 1.884, "forwardPE": -45.166664, "volume": 1149904, "regularMarketVolume": 1149904, "averageVolume": 2831408, "averageVolume10days": 2043250, "averageDailyVolume10Day": 2043250, "bid": 8.11, "ask": 8.18, "bidSize": 400, "askSize": 400, "marketCap": 1681983232, "fiftyTwoWeekLow": 4.03, "fiftyTwoWeekHigh": 8.88, "priceToSalesTrailing12Months": 4.4003787, "fiftyDayAverage": 7.4064, "twoHundredDayAverage": 6.04895, "currency": "USD", "enterpriseValue": 2291629568, "profitMargins": -0.38179, "floatShares": 192211517, "sharesOutstanding": 206886000, "sharesShort": 24805829, "sharesShortPriorMonth": 21805154, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.119899996, "heldPercentInsiders": 0.01149, "heldPercentInstitutions": 0.86481005, "shortRatio": 9.06, "shortPercentOfFloat": 0.120900005, "impliedSharesOutstanding": 217920000, "bookValue": -2.302, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -145932992, "trailingEps": -0.73, "forwardEps": -0.18, "pegRatio": -0.52, "enterpriseToRevenue": 5.995, "enterpriseToEbitda": -43.477, "52WeekChange": 0.20875907, "SandP52WeekChange": 0.24014747, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "BCRX", "underlyingSymbol": "BCRX", "shortName": "BioCryst Pharmaceuticals, Inc.", "longName": "BioCryst Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 762791400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "96bb866f-1671-37bb-8fb4-22c003011687", "messageBoardId": "finmb_25594", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.13, "targetHighPrice": 30.0, "targetLowPrice": 7.0, "targetMeanPrice": 14.45, "targetMedianPrice": 11.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 272027008, "totalCashPerShare": 1.315, "ebitda": -52709000, "totalDebt": 850641024, "quickRatio": 2.64, "currentRatio": 2.816, "totalRevenue": 382236000, "revenuePerShare": 1.902, "returnOnAssets": -0.06908, "freeCashflow": -26134124, "operatingCashflow": -83867000, "revenueGrowth": 0.325, "grossMargins": 0.47055998, "ebitdaMargins": -0.1379, "operatingMargins": 0.080129996, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]